COVID19 survivors suffer from persistent respiratory symptoms and functional limitations after the acute infection. Longitudinal studies after SARS-CoV2 infection showed impairment in lung function exercise capacity and Lung imaging abnormalities. In this lecture, we review possible post covid pulmonary involvement with a focus on whether they develop fibrosis. We also review the latest evidence on the long term follow up. Possible treatment strategies are discussed including antifibrotic therapy, mesenchymal cell therapy, prolonged steroids therapy and pulmonary rehabilitation. We conclude with recommendations for pulmonary follow up and post covid clinic design.